Rodetis will also continue to serve as the company's treasurer.
Global medical technology company Becton, Dickinson and Company (BD) announced that it has appointed Gred Rodetis as senior vice president of investor relations.
Rodetis will also continue to serve in his role as treasurer.
In a press release, BD chief financial officer and executive vice president Chris DelOrefice said, “Greg's deep knowledge of BD, coupled with his expertise of the capital markets and existing relationships with the investment banking community, make him well-positioned to lead our investor relations function and serve as a valued partner to this important stakeholder group as BD continues to deliver on its growth strategy.”
SOURCE
(October 17, 2023); BD (Bection, Dickinson and Company); BD Names Greg Rodetis as Senior Vice President of Investor Relations; https://www.prnewswire.com/news-releases/bd-names-greg-rodetis-as-senior-vice-president-of-investor-relations-301958983.html
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.